Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd Stock: price and insider trades · China
西点药业
No insider purchase over the last 90 days. The latest, by 石英秀, was filed 29 Aug 2025.
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd: what insiders have been doing
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd is a Health Care company. Its directors and officers file their transactions with SSE / SZSE (CSRC). No insider at Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd has published a filing in the past twelve months. The most recent one dates from 29 August 2025.
Since 2025, the database holds 1 purchase and 2 sales by insiders of the company.
In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- -2.2%Entry CN¥31.37 · Close at T+90 CN¥30.67
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 20,000 shares27.0% of flowA股XSHESZSE:173000009476877100Canonical exit: 27 Nov 2025 (T+90)
- 21,200 shares30.0% of flowA股XSHESZSE:173000009412040640
- 30,000 shares43.0% of flowA股XSHESZSE:173000009292924000
3 of 3 declarations
About Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd
西点药业 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHE market. It focuses on the development and commercialization of innovative pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
